For the year ending 2025-12-31, JAZZ had -$1,020,965K decrease in cash & cash equivalents over the period. $1,297,021K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -356,148 |
| Acquired in-process research and development | 947,862 |
| Intangible asset amortization | 654,661 |
| Share-based compensation | 291,133 |
| Acquisition accounting inventory fair value step-up adjustment | 147,948 |
| Depreciation | 41,636 |
| Non-cash interest expense | 32,542 |
| Provision for losses on accounts receivable and inventory | 19,108 |
| Deferred tax benefit | -444,971 |
| Impairment of property, plant and equipment | 0 |
| Other non-cash transactions | -3,103 |
| Accounts receivable | 106,279 |
| Inventories | 86,041 |
| Prepaid expenses and other assets | -29,030 |
| Accounts payable | 39,851 |
| Accrued liabilities | 77,096 |
| Income taxes payable | 37,224 |
| Other liabilities | 28,018 |
| Net cash provided by operating activities | 1,355,773 |
| Acquisition of investments | 1,830,275 |
| Asset acquisition, net of cash acquired | 858,053 |
| Acquisition of intangible assets | 108,500 |
| Purchases of property, plant and equipment | 58,752 |
| Acquired in-process research and development | 42,500 |
| Proceeds from sale of an asset | 28,167 |
| Proceeds from maturity of investments | 1,360,000 |
| Net cash used in investing activities | -1,509,913 |
| Repayments of long-term debt | 781,000 |
| Share repurchases | 125,023 |
| Payment of employee withholding taxes related to share-based awards | 75,220 |
| Proceeds from employee equity incentive and purchase plans | 107,863 |
| Repayment of 2024 notes | 0 |
| Payment of debt modification costs | 0 |
| Net proceeds from issuance of 2030 notes | 0 |
| Net cash provided by (used in) financing activities | -873,380 |
| Effect of exchange rates on cash and cash equivalents | 6,555 |
| Net increase (decrease) in cash and cash equivalents | -1,020,965 |
| Cash and cash equivalents, at beginning of period | 2,412,864 |
| Cash and cash equivalents, at end of period | 1,391,899 |
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ)